CN114469826A - 一种凝胶型浙麦冬美白面膜及其制备方法 - Google Patents
一种凝胶型浙麦冬美白面膜及其制备方法 Download PDFInfo
- Publication number
- CN114469826A CN114469826A CN202210081172.0A CN202210081172A CN114469826A CN 114469826 A CN114469826 A CN 114469826A CN 202210081172 A CN202210081172 A CN 202210081172A CN 114469826 A CN114469826 A CN 114469826A
- Authority
- CN
- China
- Prior art keywords
- ophiopogon japonicus
- extract
- add
- whitening
- ophiopogon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 244000248557 Ophiopogon japonicus Species 0.000 title claims description 110
- 239000000284 extract Substances 0.000 claims abstract description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 64
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 53
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 53
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 48
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 47
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 39
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000008367 deionised water Substances 0.000 claims abstract description 36
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 36
- 239000010495 camellia oil Substances 0.000 claims abstract description 24
- 239000003623 enhancer Substances 0.000 claims abstract description 21
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 19
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 19
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 19
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 18
- 229960000458 allantoin Drugs 0.000 claims abstract description 18
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 17
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 17
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 17
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 208000003351 Melanosis Diseases 0.000 claims abstract description 13
- 238000010521 absorption reaction Methods 0.000 claims abstract description 12
- 239000008139 complexing agent Substances 0.000 claims abstract description 11
- 241001448424 Ophiopogon Species 0.000 claims abstract description 10
- 229930195210 Ophiopogon Natural products 0.000 claims abstract description 10
- 206010008570 Chloasma Diseases 0.000 claims abstract description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 6
- 206010000496 acne Diseases 0.000 claims abstract description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 3
- 229960001631 carbomer Drugs 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 239000000047 product Substances 0.000 claims description 24
- 230000001815 facial effect Effects 0.000 claims description 18
- 235000011187 glycerol Nutrition 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 229940085237 carbomer-980 Drugs 0.000 claims description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 14
- 229920000053 polysorbate 80 Polymers 0.000 claims description 14
- 229920001661 Chitosan Polymers 0.000 claims description 13
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 claims description 13
- 229930002600 steroidal saponin Natural products 0.000 claims description 13
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 9
- 229930003451 Vitamin B1 Natural products 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- 229960003495 thiamine Drugs 0.000 claims description 9
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 9
- 235000010374 vitamin B1 Nutrition 0.000 claims description 9
- 239000011691 vitamin B1 Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- QRCTUFJCBXMBPP-UHFFFAOYSA-N Ovaliflavanone A Chemical compound O1C=2C(CC=C(C)C)=C(O)C(CC=C(C)C)=CC=2C(=O)CC1C1=CC=CC=C1 QRCTUFJCBXMBPP-UHFFFAOYSA-N 0.000 claims description 7
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 229930003949 flavanone Natural products 0.000 claims description 7
- 235000011981 flavanones Nutrition 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 150000005856 steroid saponins Chemical class 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 150000002208 flavanones Chemical class 0.000 claims description 6
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 5
- 241001149911 Isopoda Species 0.000 claims description 4
- 229940099352 cholate Drugs 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960003964 deoxycholic acid Drugs 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 235000017709 saponins Nutrition 0.000 claims description 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 3
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- AAYACJGHNRIFCT-YRJJIGPTSA-M sodium glycochenodeoxycholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)CC1 AAYACJGHNRIFCT-YRJJIGPTSA-M 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 3
- 239000003480 eluent Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- IYPNVUSIMGAJFC-HLEJRKHJSA-M sodium;2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)CC1 IYPNVUSIMGAJFC-HLEJRKHJSA-M 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 abstract description 26
- 108060008724 Tyrosinase Proteins 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 19
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- 229930190714 ophiopogonone Natural products 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- -1 oxygen heterocyclic compounds Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-M cholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 240000001548 Camellia japonica Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000018597 common camellia Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 238000000199 molecular distillation Methods 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- LYCAIKOWRPUZTN-NMQOAUCRSA-N 1,2-dideuteriooxyethane Chemical compound [2H]OCCO[2H] LYCAIKOWRPUZTN-NMQOAUCRSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 241000226556 Leontopodium alpinum Species 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- DSTDMPAJBBOFCE-UHFFFAOYSA-N cremastranone Chemical compound C1=C(O)C(OC)=CC=C1CC1C(=O)C2=C(O)C(OC)=C(O)C=C2OC1 DSTDMPAJBBOFCE-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940084750 sophora flavescens root extract Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种凝胶型浙麦冬美白面膜及其制备方法,包括以下重量百分比的组分:麦冬高异黄酮提取物1‑6%、吸收促进剂0.05‑0.5%、络合剂1‑7%、美白增强剂0.04‑0.4%、卡波姆980 0.2‑0.8%、透明质酸钠0.01‑0.05%、甘油10‑20%、乙二醇1‑5%、茶油0.05‑0.1%、吐温‑80 0.05‑2%、氮酮0.05‑2%、尼泊金乙酯0.1‑0.5%、尿囊素0.05‑0.5%、余量为去离子水。本发明配方无毒、无刺激、安全性能高,且浙麦冬高异黄酮提取物能有效抑制酪氨酸酶活性,有效减轻黄褐斑及痤疮引起的黑斑且来源丰富,且属于可再生资源,绿色环保。
Description
技术领域
本发明属于化妆品技术领域,具体涉及一种凝胶型浙麦冬美白面膜及其制备方法。
背景技术
面膜是集清洁、护理、营养于一体的面部皮肤用化妆品,深受成年人尤其是女性消费者喜爱。随着消费心理的成熟,人们不仅要求面膜可以达到清洁、护理、营养的基本功效,还进一步追求开发面膜的美白、抗衰老等高级功效。目前,面膜的种类繁多,分为贴式面膜、撕拉面膜、凝胶面膜等。其中凝胶型面膜为凝胶状膏体,易于均匀涂抹在面部,可以阻隔面部皮肤与空气的接触,有效防止水分的蒸发,增加角质层的湿度,软化角质;还能使皮肤表面毛孔扩张,有利于营养成分吸收。
皮肤颜色的深浅受多种因素调控,主要取决于黑色素的含量及分布。黑色素是一种氨基酸衍生物,是酪氨酸或3,4-二羟苯丙氨酸经过一连串化学反应所形成的,其常以聚合的方式存在。黑色素由人表皮基底层中的黑色素细胞合成,当紫外线照射到皮肤上,肌肤就会处于“自我防护”的状态,激活酪氨酸酶的活性,催化酪氨酸或3,4-二羟苯丙氨酸氧化生成黑色素,来保护我们的皮肤细胞。黑色素又经由细胞代谢的层层移动,到了肌肤表皮层形成雀斑、晒斑、黑斑等。
随着近年来对中药药效活性物质的研究不断深入与技术现代化的发展,越来越多的中药被发现具有美容的功效而被运用到护肤品中。浙麦冬是浙江省最为著名的道地药材“浙八味”之一,用于急性咳嗽、喉咙肿痛和心脑血管等疾病的治疗已有上千年的历史。2002年,麦冬被国家卫健委批准为可用于保健食品的“药食同源”中药;此外,其在日本及越南等东南亚国家也常作为功能食品和地方药品使用。研究表明,黄酮类成分是其主要药效物质之一,在我们前期的研究中发现,浙麦冬块根及须根中均含有特征性黄酮类成分,包括甲基麦冬黄烷酮A,甲基麦冬黄烷酮B,6-醛基异麦冬黄烷酮A和6-醛基异麦冬黄烷酮B等均具有抑制酪氨酸酶的作用,从而阻断细胞内黑色素的生成,因此,可用于美白等作用的护肤品中,达到美容祛斑的作用。而此前麦冬提取物已被用于多个美白面膜制备的专利中,如中国专利CN111956543A公开了一种美白抗敏的大麻叶面膜,所述中药组合物由以下重量份的原料组成:水60-92%、丙二醇1-6%、甘油1-6%、扭刺仙人掌茎提取物0.05-3%、麦冬根提取物0.05-3%、苦参根提取物0.05-3%、海藻糖0.1-6%、丁二醇0.1-6%、雪莲花提取物0.05-3%、高山火绒草花/叶提取物0.05-3%、酒石酸0.001-0.3%、EDTA二钠0.001-0.3%、亚硫酸钠0.001-0.3%、焦亚硫酸钠0.001-0.3%、银耳提取物0.1-2%、对羟基苯乙酮0.1-1%、1,2-己二醇0.1-1%、黄原胶0.05-0.2%、尿囊素0.05-0.2%、大麻叶提取物0.05-5%、聚丙烯酸钠0.05-0.2%。制备的面膜中含有0.05-3%麦冬根提取物。中国专利CN113041205A一种美白保湿中药面膜及其制备方法,以菟丝子10-300重量份、红花10-200重量份、白蒺藜10-100重量份、麦冬1-50重量份、韭菜叶50-500重量份、黄土5-50重量份、植物油10-100重量份、淀粉100-1000重量份作为原料,经过粉碎、超声提取、调节pH等步骤,制得一种美白保湿中药面膜。尽管以上面膜制备方法所述的配方中含有麦冬提取物,但是从配方组成看均不是以麦冬提取物为主药,而且并未明确面膜中麦冬功效成分的结构类型及其含量标准。因而,基于我们已有研究实验结果,开发一种含有浙麦冬高异黄酮提取物的中药面膜将具有很好的美白功效和市场潜力。
发明内容
针对现有技术中存在的问题,本发明设计的目的在于提供一种凝胶型浙麦冬美白面膜及其制备方法,具体通过以下技术方案加以实现:
所述的一种凝胶型浙麦冬美白面膜,包括以下重量百分比的组分:浙麦冬高异黄酮提取物1-6%、吸收促进剂0.05-0.5%、络合剂1-7%、美白增强剂0.04-0.4%、卡波姆9800.2-0.8%、透明质酸钠0.01-0.05%、甘油10-20%、乙二醇1-5%、茶油0.05-0.1%、吐温-80 0.05-2%、氮酮0.05-2%、尼泊金乙酯0.1-0.5%、尿囊素0.05-0.5%、余量为去离子水。
进一步地,浙麦冬高异黄酮提取物6%、吸收促进剂0.4%、络合剂1%、美白增强剂0.4%、卡波姆980 0.2%、透明质酸钠0.01%、甘油18%、乙二醇1%、茶油0.05%、吐温-802%、氮酮2%、尼泊金乙酯0.1%、尿囊素0.05%、余量为去离子水。其中美白增强剂中维生素B1 0.2%,微生物C 0.2%,吸收促进剂中浙麦冬甾体皂苷提取物0.3%,甘氨胆酸钠0.1%。
进一步地,浙麦冬高异黄酮提取物是指:浙麦冬高异黄酮提取物按干燥品计,所含甲基麦冬黄烷酮A,甲基麦冬黄烷酮B,6-醛基异麦冬黄烷酮A和6-醛基异麦冬黄烷酮B的总量不得少于10%。
进一步地,吸收促进剂由浙麦冬甾体皂苷提取物和胆酸盐组成;所述浙麦冬甾体皂苷与胆酸盐的质量比为3:1;浙麦冬甾体皂苷提取物按干燥品计算,含麦冬总皂苷以鲁斯可苷元计,不得少于5%,胆酸盐选用甘氨胆酸钠、甘氨鹅脱氧胆酸钠、牛磺胆酸钠、牛磺鹅脱氧胆酸钠、脱氧胆酸钠中的一种或两种以上。
进一步地,所述络合剂为EDTA-二钠或壳聚糖中的一种或二种,EDTA-二钠的重量百分比为2-3%,壳聚糖的重量百分比为1-4%。
进一步地,美白增强剂为维生素B1和维生素C中的一种或二种。
进一步地,茶油为冷榨山茶油,山茶油媲美橄榄油,脂肪酸组成与橄榄油相似。制备包括以下步骤:
选取成熟山茶籽,40-50℃烘干干燥至含水量3-6%,干燥后的山茶籽送入脱壳机脱壳;将脱壳后的山茶籽冷榨压榨出山茶油,榨膛温度为100~150℃,出油温度为80~120℃;压榨出的山茶油通过板框压滤机除去固体杂质;将板框压滤后的山茶油于-5℃~5℃冬化;冬化后的山茶油经过分子蒸馏除去山茶油中的游离脂肪酸、油脂过氧化产物、水分及其他低沸点物质;分子蒸馏后的山茶油用白土、活性炭和氧化铝混合物作为过滤介质过滤除去杂质和色素即得成品。
进一步地,浙麦冬高异黄酮提取物的制备方法为:
1)浙麦冬粉末加入10-20倍量的70%的乙醇,80℃加热回流提取1-2h,提取1-3次,滤液浓缩得到浙麦冬提取物浸膏,加去离子水稀释成浓度至每1ml相当于原有药材0.1-1g的水提取物;
2)取步骤1)的提取物,按提取物与树脂的固液比为1-10mL/g上样于D101大孔树脂,依次用蒸馏水、60%的乙醇、90%乙醇洗脱,收集90%乙醇洗脱液,减压浓缩,真空冷冻干燥得到提取物1,即浙麦冬高异黄酮提取物;其中,收集60%乙醇洗脱液,减压浓缩,真空冷冻干燥得到提取物2,即浙麦冬甾体皂苷提取物。
所述的一种凝胶型浙麦冬美白面膜的制备方法,包括以下步骤:
1)A相的制备:将配方量的卡波姆980倒入适量去离子水中搅拌,待分散均匀后加入配方量的尿囊素和氮酮继续搅拌加热至80℃恒温15min;
2)B相的制备:在配方量的甘油中加入配方量的透明质酸钠搅拌,待透明质酸分散均匀后加入适量蒸馏水继续搅拌,待体系均匀后再加入配方量的茶油和乙二醇并加热搅拌至80℃恒温15min;
3)C相的制备:将配方量的浙麦冬高异黄酮提取物、促进吸收剂、美白增强剂加入适量的去离子水中,并滴加少量乙醇,温热至55℃并用超声波溶解;
4)将B相组分加入到A相组分中,加入配量的络合剂,于80℃搅拌15min后冷却至55℃,加入溶解均一的C相组分,并使产品继续冷却至45℃,然后依次加入配方量的尼泊金乙酯和吐温-80,加去离子水至100mL,搅拌均匀即得膏体;
5)将膏体置于真空搅拌机内,加入去离子水补足余量,真空搅拌均匀,包装即得凝胶型浙麦冬美白面膜。
进一步地,步骤1)中适量去离子水占总去离子水用量的70-80%,步骤4)中络合剂为EDTA-二钠和壳聚糖两者中的一种或两种。
一种凝胶型浙麦冬美白面膜在减轻黄褐斑及痤疮引起的黑斑上应用。
酪氨酸酶又称为多酚氧化酶,是生物体内黑色素生物合成过程中的关键限速酶。在黑色素形成的过程中,酪氨酸酶可催化L-酪氨酸生成L-多巴,L-多巴逐步氧化成多巴醌,进而形成色素颗粒,其过高的活性会引发色素沉积、黄褐斑、雀斑、老年斑等症状。因而酪氨酸酶抑制活性常被用于评价美白化妆品的祛斑美白功效,如曲酸、熊果苷等酪氨酸酶抑制剂已作为美白剂在化妆品、护肤品中得到广泛应用。
浙麦冬中的特征性成分高异黄酮是一类天然存在的独特黄酮类结构化合物,其母核结构比含两个芳香环的氧杂环化合物的异黄酮在B和C环之间多一个碳原子。对该类化合物的生物学研究表明,其具有多种生理功能,如强效抗真菌,抗氧化剂,抗增殖,抗炎,抗组胺,抗过敏,细胞毒性,抗诱变,和抗血管生成活性(如cremastranone)。特别地,该类化合物也具有蛋白质酪氨酸激酶(PTK)抑制活性。
本发明研究表明,浙麦冬4种高异黄酮单体成分及其混合提取物具有显著的抑制酪氨酸酶的活性,能有效减轻黄褐斑及痤疮引起的黑斑,具有祛斑美白、保湿的作用。同时本发明研究表明,麦冬水提物酪氨酸酶抑制活性弱,麦冬多糖不具有酪氨酸酶抑制活性,并且麦冬多糖粘性强,不利于用于面膜的制备。因此,采用麦冬高异黄酮提取物作为主要面膜中功能活性成分,具有酪氨酸酶抑制活性物质得到有效富集,效果和安全性更高。
本面膜配方中的其他的辅料成分是面膜中常用且经实验证明了安全性。如甘油、尿囊素具有保湿的功效,透明质酸钠本身是人体皮肤的构成之一,存在于结缔组织中,由于透明质酸钠含有大量的羧基和羟基,在水溶液中形成分子内和分子间的氢键,具有良好的保湿作用。壳聚糖和橙皮素能通过分子中的氨基、羟基络合面部的Pb2+、Hg2+、Ni2+等重金属离子,除去皮肤中的重金属离子,降低重金属的危害。
本发明与现有技术相比,具有以下有益效果:
1)本发明中使用的浙麦冬高异黄酮提取物能有效抑制酪氨酸酶活性,有效减轻黄褐斑及痤疮引起的黑斑。且提取物物中功能成分清晰,效果确切,过敏原筛查明确清晰。浙麦冬高异黄酮提取物从天然植物浙麦冬中提取制备而得,来源丰富,且属于可再生资源,绿色环保;
2)本发明配方在利用浙麦冬高异黄酮提取物作为功能因子时,以浙麦冬甾体皂苷提取物作为一种天然的非离子型表面活性剂,实现了浙麦冬资源的高效综合利用,利用皂苷的结构特性能够在水中形成微小的胶体粒子,通过形成胶束作用将配方中的活性成分吸附在一起,增加细胞间水溶性通道的渗透性,促进水溶性物质的吸收;并且低浓度的胆酸盐可以水化并抽提细胞间脂质,从而增加了提取物在细胞间水性通道内的扩散,同时胆酸盐可作为酶抑制剂,通过影响酶的活性,改变多肽、蛋白质构象等不同的机制维持药物的稳定,将其与表面活性剂浙麦冬甾体皂苷提取物复配能够明显增大美白面膜中有效成分的吸收;
3)本发明配方中的所有组分均为无毒、无刺激、安全性能高的成分,大部分成分为天然植物提取活性成分,可以放心使用。
附图说明
图1为高异黄酮标准品测定HPLC色谱图;
图2浙麦冬高异黄酮提取物中高异黄酮含量测定HPLC色谱图;
图中,1为甲基麦冬黄烷酮A;2为甲基麦冬黄烷酮B;3为6-醛基异麦冬黄烷酮A;4为6-醛基异麦冬黄烷酮B。
具体实施方式
以下结合具体实施例对本发明做进一步详细描述,以便更好地理解本技术方案,本发明中所涉及的百分比除非另有说明,均是以重量百分比计算。
实施例1
浙麦冬高异黄酮提取物3%、维生素C 0.3%、浙麦冬甾体皂苷提取物0.3%、甘氨胆酸钠0.1%、卡波姆980 0.5%、透明质酸钠0.02%、甘油15%、乙二醇3%、茶油0.1%、吐温-80 1%、氮酮1%、尼泊金乙酯0.3%、尿囊素0.3%、壳聚糖1%,余量为去离子水。
制备方法:
1)A相的制备:将0.5重量份卡波姆980倒入55重量份的去离子水中搅拌,待分散均匀后加入0.3重量份尿囊素和1重量份氮酮继续搅拌加热至80℃恒温15min;
2)B相的制备:在15重量份甘油中加入0.02重量份透明质酸钠搅拌,待透明质酸分散均匀后加入适量蒸馏水继续搅拌,待体系均匀后再加入0.1重量份茶油和3重量份乙二醇并加热搅拌至80℃恒温15min;
3)C相的制备:加入提取出来的3重量份浙麦冬高异黄酮提取物,0.3重量份浙麦冬甾体皂苷提取物,0.1重量份甘氨胆酸钠、0.3重量份维生素C和适量水,并滴加少量乙醇,温热至55℃并用超声波溶解;
4)将B相组分加入到A相组分中,加入1重量份壳聚糖,于80℃搅拌15min后冷却。待冷却至55℃,加入溶解均一的C相组分,并使产品继续冷却。待产品冷却至45℃加入0.3重量份尼泊金乙酯,最后加入1重量份吐温-80,加去离子水,搅拌均匀即得膏体;
5)将膏体置于真空搅拌机内,加入去离子水补足余量,真空搅拌均匀,包装即得。
实施例2
麦冬高异黄酮提取物5%、维生素C 0.2%、浙麦冬甾体皂苷提取物0.36%、甘氨胆酸钠0.12%、卡波姆980 0.6%、透明质酸钠0.04%、甘油20%、乙二醇4%、茶油0.1%、吐温-80 2%、氮酮2%、尼泊金乙酯0.4%、尿囊素0.4%,EDTA-二钠3%,余量为去离子水。
制备方法:
1)A相的制备:将0.6重量份卡波姆980倒入45重量份的去离子水中搅拌,待分散均匀后加入0.4重量份尿囊素和2重量份氮酮继续搅拌加热至80℃恒温15min;
2)B相的制备:在20重量份甘油中加入0.04重量份透明质酸钠搅拌,待透明质酸分散均匀后加入适量蒸馏水继续搅拌,待体系均匀后再加入0.1重量份茶油和4重量份乙二醇并加热搅拌至80℃恒温15min。
3)C相的制备:加入提取出来的5重量份浙麦冬高异黄酮提取物,0.4重量份浙麦冬甾体皂苷提取物,0.13重量份甘氨胆酸钠、0.2重量份维生素C和适量水、并滴加少量乙醇,温热至55℃并用超声波溶解。
4)将B相组分加入到A相组分中,加入3重量份EDTA-二钠,于80℃搅拌15min后冷却。待冷却至55℃,加入溶解均一的C相组分,并使产品继续冷却。待产品冷却至45℃加入0.4重量份尼泊金乙酯,最后加入2重量份吐温-80,加去离子水,搅拌均匀即得膏体;
5)将膏体置于真空搅拌机内,加入去离子水补足余量,真空搅拌均匀,包装即得。
实施例3
麦冬高异黄酮提取物2%、维生素B1 0.3%、浙麦冬甾体皂苷提取物0.21%、甘氨胆酸钠0.07%、卡波姆980 0.8%、透明质酸钠0.03%、甘油15%、乙二醇5%、茶油0.05%、吐温-80 1.5%、氮酮1.5%、尼泊金乙酯0.5%、尿囊素0.2%、EDTA-二钠2%,余量为去离子水。
制备方法:
1)A相的制备:将0.8重量份卡波姆980倒入50重量份去离子水中搅拌,待分散均匀后加入0.2重量份尿囊素和1.5重量份氮酮继续搅拌加热至80℃恒温15min;
2)B相的制备:在重量份甘油中加入0.03重量份透明质酸钠搅拌,待透明质酸分散均匀后加入适量蒸馏水继续搅拌,待体系均匀后再加入0.05重量份茶油和5重量份乙二醇并加热搅拌至80℃恒温15min;
3)C相的制备:加入提取出来的2重量份浙麦冬高异黄酮提取物,0.2重量份浙麦冬甾体皂苷提取物、0.06重量份甘氨胆酸钠,0.3重量份维生素B1和适量水,并滴加少量乙醇,温热至55℃并用超声波溶解;
4)将B相组分加入到A相组分中,加入2重量份EDTA-二钠2%,于80℃搅拌15min后冷却。待冷却至55℃,加入溶解均一的C相组分,并使产品继续冷却。待产品冷却至45℃加入0.5重量份尼泊金乙酯,最后加入1.5重量份吐温-80,加去离子水,搅拌均匀即得膏体;
5)将膏体置于真空搅拌机内,加入去离子水补足余量,真空搅拌均匀,包装即得。
实施例4
麦冬高异黄酮提取物4%、维生素B1 0.2%、浙麦冬甾体皂苷提取物0.3%、甘氨胆酸钠0.1%、卡波姆980 0.4%、透明质酸钠0.05%、甘油10%、乙二醇2%、茶油0.05%、吐温-80 0.05%、氮酮0.05%、尼泊金乙酯0.5%、尿囊素0.5%、壳聚糖4%,余量为去离子水。
制备方法:
1)A相的制备:将0.4重量份卡波姆980倒入60重量份去离子水中搅拌,待分散均匀后加入0.5重量份尿囊素和0.05重量份氮酮继续搅拌加热至80℃恒温15min;
2)B相的制备:在10重量份甘油中加入0.05重量份透明质酸钠搅拌,待透明质酸分散均匀后加入适量蒸馏水继续搅拌,待体系均匀后再加入0.05重量份茶油和2重量份乙二醇并加热搅拌至80℃恒温15min;
3)C相的制备:加入提取出来的4重量份浙麦冬高异黄酮提取物,0.3重量份浙麦冬甾体皂苷提取物、0.1重量份甘氨胆酸钠,0.2重量份维生素B1和适量水,并滴加少量乙醇,温热至55℃并用超声波溶解;
4)将B相组分加入到A相组分中,加入4重量份壳聚糖,于80℃搅拌15min后冷却。待冷却至55℃,加入溶解均一的C相组分,并使产品继续冷却。待产品冷却至45℃加入0.5重量份尼泊金乙酯,最后加入0.05重量份吐温-80,加去离子水,搅拌均匀即得膏体。
5)将膏体置于真空搅拌机内,加入去离子水补足余量,真空搅拌均匀,包装即得。
实施例5
麦冬高异黄酮提取物6%、维生素B1 0.2%、维生素C 0.2%、浙麦冬甾体皂苷提取物0.3%、甘氨胆酸钠0.1%、卡波姆980 0.2%、透明质酸钠0.01%、甘油18%、乙二醇1%、茶油0.05%、吐温-80 2%、氮酮2%、尼泊金乙酯0.1%,尿囊素0.05%,壳聚糖3%,余量为去离子水。
制备方法:
1)A相的制备:将0.2重量份卡波姆980倒入50重量份去离子水中搅拌,待分散均匀后加入0.05重量份尿囊素和2重量份氮酮继续搅拌加热至80℃恒温15min;
2)B相的制备:在18重量份甘油中加入0.01重量份透明质酸钠搅拌,待透明质酸分散均匀后加入适量蒸馏水继续搅拌,待体系均匀后再加入0.05重量份茶油和1重量份乙二醇并加热搅拌至80℃恒温15min;
3)C相的制备:加入提取出来的6重量份浙麦冬高异黄酮提取物,0.3重量份浙麦冬甾体皂苷提取物,0.1重量份甘氨胆酸钠、0.2重量份维生素B1和适量水,并滴加少量乙醇,温热至55℃并用超声波溶解;
4)将B相组分加入到A相组分中,加入3重量份壳聚糖,于80℃搅拌15min后冷却。待冷却至55℃,加入溶解均一的C相组分,并使产品继续冷却。待产品冷却至45℃加入0.1重量份尼泊金乙酯,最后加入2重量份吐温-80,加去离子水,搅拌均匀即得膏体;
5)将膏体置于真空搅拌机内,加入去离子水补足余量,真空搅拌均匀,包装即得。
实验例
实验例1:浙麦冬高异黄酮提取物中四种高异黄酮的含量分析
本实施例所采用分析浙麦冬高异黄酮提取物及产品中高异黄酮含量的HPLC条件为:Waters HPLC系统包括e2695四元泵分离单元,柱温箱和2998二极管阵列检测器;色谱柱Thermo C18色谱柱(4.6×250mm,5.0μm);流动相由乙腈(A)和水(B)组成,梯度洗脱方案为:0~5min,35%A;5~20min,35~40%A;20~50min,40~70%A。柱温35℃;流速1mL/min,检测波长285nm。进样量根据样品浓度一般为5~20μL。4种浙麦冬高异黄酮标准品和样品的HPLC检测图谱见图1和2。
实验例2:浙麦冬高异黄酮提取物酪氨酸酶抑制活性研究
磷酸盐(pH 6.8,0.05mol/L)缓冲体配置:
酪氨酸酶溶液的配置:精密称取酪氨酸酶,用磷酸钠缓冲液配成5×10-6mol/L的酶液,-20℃冷冻保存,用前4℃解冻。
L-多巴(L-DOPA)溶液的配置:精密称取L-DOPA,加入磷酸盐缓冲液溶解,配得5.0×10-4mol/L的L-多巴溶液。
样品溶液的配置:将麦冬高异黄酮提取物,配制成不同浓度的高异黄酮复合液。
测定方法:酪氨酸酶催化底物L-DOPA生成的产物在475nm处特征吸收峰,利用抑制动力学方法,在3mL的磷酸盐(pH 6.8,0.05mol/L)缓冲体系中,固定酪氨酸酶的浓度2.08×10-7mol/L,将其与不同浓度的高异黄酮提取物在室温条件下孵化3h,使其充分反应后,加入底物L-DOPA(5.0×10-4mol/L),每隔5s测定一次反应体系在475nm处的吸光度,通过关系式(1),计算在含有不同浓度高异黄酮体系下酪氨酸酶的相对活性。曲酸作为阳性对照。式中R0、R分别为不加抑制剂和添加不同浓度抑制剂时反应体系的吸光度随时间的变化率。
相对活性(%)=(R/R0)×100% (1)
表1浙麦冬高异黄酮提取物酪氨酸酶活性抑制率
实验结果表明,浙麦冬高异黄酮提取物具有明显的酪氨酸酶活性抑制效果。说明本发明能有效减轻黄褐斑及痤疮引起的黑斑,具有祛斑美白、保湿的作用。
实验例3:浙麦冬多糖、水提取物的氨酸酶抑制活性研究
采用与实验例2相同的方法,对不同浓度浙麦冬多糖、麦冬水提物对酪氨酸酶抑制活性进行测定,结果见表2。
表2麦冬多糖、水提取物酪氨酸酶活性抑制率
实验结果表明,与浙麦冬高异黄酮提取物相比,浙麦冬多糖及水提物对酪氨酸酶活性抑制率较低,且各浓度对酪氨酸酶均无明显抑制作用,说明浙麦冬多糖、水提取物并非浙麦冬美白的有效成分。
实验例4:浙麦冬高异黄酮提取物与美白增强剂协同作用抑制酪氨酸酶活性研究
按本发明实施例中浙麦冬高异黄酮提取物与不同比例增强剂配制美白增强复合液。按照实施例1配制的浙麦冬高异黄酮提取物、美白增强剂复合液标记为复合液1,按照实施例2配制的浙麦冬高异黄酮提取物、美白增强剂复合液标记为复合液2,依此类推。采用与实验例1相同的方法测定复合液和浙麦冬高异黄酮提取物对酪氨酸酶的抑制活性,浙麦冬高异黄酮提取物浓度为3%(按生药量计算),结果见表3。
表3各样品酪氨酸酶活性抑制率
实验例5:基础理化指标
参照国家标准QB/T1857-2013和QB/T2660-2004,对面膜的色泽、气味、涂展性、黏稠度、产品结构和稳定性进行测试,确定是否符合国家标准。本面膜试样的相关理化检测指标、感官及稳定性实验结果见表4。
表4理化检测指标、感官及稳定性实验结果
实验例6:皮肤刺激性测试
选择30名年龄为20~30岁的志愿者作为受试对象,在其左手背将面膜均匀涂抹,每天2次,6h后观察皮肤的反应。经过一周的实验观察,30名皮肤健康的在校大学生志愿者涂有面膜液的左手背皮肤比没有涂面膜液的右手背皮肤要柔软润泽一些,未见发红、起疹、起水泡等现象,也无发痒、过敏、疼痛等现象,得出该面膜无刺激性。
Claims (10)
1.一种凝胶型浙麦冬美白面膜,其特征在于包括以下重量百分比的组分:浙麦冬高异黄酮提取物1-6%、吸收促进剂0.05-0.5%、络合剂1-7%、美白增强剂0.04-0.4%、卡波姆9800.2-0.8%、透明质酸钠0.01-0.05%、甘油10-20%、乙二醇1-5%、茶油0.05-0.1%、吐温-800.05-2%、氮酮0.05-2%、尼泊金乙酯0.1-0.5%、尿囊素0.05-0.5%、余量为去离子水。
2.如权利要求1所述的一种凝胶型浙麦冬美白面膜,其特征在于所述浙麦冬高异黄酮提取物6%、吸收促进剂0.4%、络合剂1%、美白增强剂 0.4%、卡波姆980 0.2%、透明质酸钠0.01%、甘油18%、乙二醇1%、茶油0.05%、吐温-80 2%、氮酮2%、尼泊金乙酯0.1%、尿囊素0.05%、余量为去离子水。
3.如权利要求1或2所述的一种凝胶型浙麦冬美白面膜,其特征在于所述浙麦冬高异黄酮提取物是指:浙麦冬高异黄酮提取物按干燥品计,所含甲基麦冬黄烷酮A,甲基麦冬黄烷酮B,6-醛基异麦冬黄烷酮A和6-醛基异麦冬黄烷酮B的总量不得少于10%。
4.如权利要求1或2所述的一种凝胶型浙麦冬美白面膜,其特征在于所述吸收促进剂由浙麦冬甾体皂苷提取物和胆酸盐组成;所述浙麦冬甾体皂苷与胆酸盐的质量比为3:1;浙麦冬甾体皂苷提取物按干燥品计算,含麦冬总皂苷以鲁斯可苷元计,不得少于5%,胆酸盐选用甘氨胆酸钠、甘氨鹅脱氧胆酸钠、牛磺胆酸钠、牛磺鹅脱氧胆酸钠、脱氧胆酸钠中的一种或两种以上。
5.如权利要求1或2所述的一种凝胶型浙麦冬美白面膜,其特征在于所述络合剂为EDTA-二钠或壳聚糖中的一种或二种,EDTA-二钠的重量百分比为2-3%,壳聚糖的重量百分比为1-4%。
6.如权利要求1或2所述的一种凝胶型浙麦冬美白面膜,其特征在于所述美白增强剂为维生素B1和维生素C中的一种或二种。
7.如权利要求1或2所述的一种凝胶型浙麦冬美白面膜,其特征在于所述浙麦冬高异黄酮提取物的制备方法为:
1)浙麦冬粉末加入10-20倍量的70%的乙醇,80℃加热回流提取1-2h,提取1-3次,滤液浓缩得到浙麦冬提取物浸膏,加去离子水稀释成浓度至每1ml相当于原有药材0.1-1g的水提取物;
2)取步骤1)的提取物,按提取物与树脂的固液比为1-10mL/g上样于D101大孔树脂,依次用蒸馏水、60%的乙醇、90%乙醇洗脱,收集90%乙醇洗脱液,减压浓缩,真空冷冻干燥得到提取物1,即浙麦冬高异黄酮提取物;其中,收集60%乙醇洗脱液,减压浓缩,真空冷冻干燥得到提取物2,即浙麦冬甾体皂苷提取物。
8.权利要求1-7任一所述的一种凝胶型浙麦冬美白面膜的制备方法,其特征在于包括以下步骤:
1)A相的制备:将配方量的卡波姆980倒入适量去离子水中搅拌,待分散均匀后加入配方量的尿囊素和氮酮继续搅拌加热至 80℃恒温15min;
2)B相的制备:在配方量的甘油中加入配方量的透明质酸钠搅拌,待透明质酸分散均匀后加入适量蒸馏水继续搅拌,待体系均匀后再加入配方量的茶油和乙二醇并加热搅拌至80℃恒温 15min;
3)C相的制备:将配方量的浙麦冬高异黄酮提取物、促进吸收剂、美白增强剂加入适量的去离子水中,并滴加少量乙醇,温热至 55℃并用超声波溶解;
4)将B相组分加入到 A相组分中,加入配量的络合剂,于80℃ 搅拌15min后冷却至 55℃,加入溶解均一的C相组分,并使产品继续冷却至45℃ ,然后依次加入配方量的尼泊金乙酯和吐温-80,加去离子水至 100mL,搅拌均匀即得膏体;
5)将膏体置于真空搅拌机内,加入去离子水补足余量,真空搅拌均匀,包装即得凝胶型浙麦冬美白面膜。
9.如权利要求8所述的一种凝胶型浙麦冬美白面膜的制备方法,其特征在于步骤1)中适量去离子水占去去离子水总量的70-80%,步骤4)中络合剂为EDTA-二钠和壳聚糖两者中的一种或两种。
10.一种凝胶型浙麦冬美白面膜在减轻黄褐斑及痤疮引起的黑斑上应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210081172.0A CN114469826B (zh) | 2022-01-24 | 2022-01-24 | 一种凝胶型浙麦冬美白面膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210081172.0A CN114469826B (zh) | 2022-01-24 | 2022-01-24 | 一种凝胶型浙麦冬美白面膜及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114469826A true CN114469826A (zh) | 2022-05-13 |
CN114469826B CN114469826B (zh) | 2023-11-14 |
Family
ID=81474544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210081172.0A Active CN114469826B (zh) | 2022-01-24 | 2022-01-24 | 一种凝胶型浙麦冬美白面膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114469826B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116785375A (zh) * | 2023-07-21 | 2023-09-22 | 深圳海创生物科技有限公司 | 一种天然植物提取物的制备方法及其在制备具有美白作用的产品中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1750762A (zh) * | 2002-12-24 | 2006-03-22 | 不二制油株式会社 | 含有高浓度的异黄酮并具有高溶解度的组合物及其制备方法 |
CN105031206A (zh) * | 2015-03-25 | 2015-11-11 | 哈尔滨泰华药业股份有限公司 | 一种抗血小板聚集的川麦冬皂苷组合物 |
CN105287290A (zh) * | 2015-11-18 | 2016-02-03 | 关美玲 | 一种美白抗衰老洁面乳及其制备方法 |
CN105342914A (zh) * | 2015-11-18 | 2016-02-24 | 关美玲 | 一种祛斑美白爽肤水及其制备方法 |
KR20160085526A (ko) * | 2015-01-08 | 2016-07-18 | 강원대학교산학협력단 | 이소플라본 함량 및 기능성이 증진된 콩 추출물의 제조방법 |
CN105816649A (zh) * | 2016-04-13 | 2016-08-03 | 华芮科技(深圳)有限公司 | 一种用于除湿止痒的中药组合物及其制备方法和用途 |
CN109528615A (zh) * | 2019-01-22 | 2019-03-29 | 湖北中医药大学 | 一种凝胶型白及美白面膜及其制备方法 |
-
2022
- 2022-01-24 CN CN202210081172.0A patent/CN114469826B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1750762A (zh) * | 2002-12-24 | 2006-03-22 | 不二制油株式会社 | 含有高浓度的异黄酮并具有高溶解度的组合物及其制备方法 |
KR20160085526A (ko) * | 2015-01-08 | 2016-07-18 | 강원대학교산학협력단 | 이소플라본 함량 및 기능성이 증진된 콩 추출물의 제조방법 |
CN105031206A (zh) * | 2015-03-25 | 2015-11-11 | 哈尔滨泰华药业股份有限公司 | 一种抗血小板聚集的川麦冬皂苷组合物 |
CN105287290A (zh) * | 2015-11-18 | 2016-02-03 | 关美玲 | 一种美白抗衰老洁面乳及其制备方法 |
CN105342914A (zh) * | 2015-11-18 | 2016-02-24 | 关美玲 | 一种祛斑美白爽肤水及其制备方法 |
CN105816649A (zh) * | 2016-04-13 | 2016-08-03 | 华芮科技(深圳)有限公司 | 一种用于除湿止痒的中药组合物及其制备方法和用途 |
CN109528615A (zh) * | 2019-01-22 | 2019-03-29 | 湖北中医药大学 | 一种凝胶型白及美白面膜及其制备方法 |
Non-Patent Citations (1)
Title |
---|
孙剑锋;王淑玲;李华;刘绪文;周晓晓;扈金东;盛晓丹;谢恬;: ""浙八味"传统中药以及相关保健食品的研究与展望", 中国当代医药, no. 32, pages 19 - 22 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116785375A (zh) * | 2023-07-21 | 2023-09-22 | 深圳海创生物科技有限公司 | 一种天然植物提取物的制备方法及其在制备具有美白作用的产品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114469826B (zh) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104013566B (zh) | 一种具有美白功效的中药组合物、其制备方法及其美容应用 | |
CN112494406A (zh) | 一种美白祛斑化妆品及其制备方法 | |
CN105381007B (zh) | 具有美白功效的外用中药组合物、制剂及其制备方法和用途 | |
CN102579972B (zh) | 一种具有祛黑眼圈功效的中药组合物、制剂及其制备方法 | |
CN112006959B (zh) | 一种含蒲公英和茶叶提取物的抗氧化美白膏霜及其制备方法 | |
CN102440928A (zh) | 具有促进皮肤微循环功效的中药组合物、制剂及其制备方法 | |
CN101647767B (zh) | 一种美白祛斑面膜用溶液及其制备方法 | |
CN106420531A (zh) | 一种含藏荆芥具有美白保湿功效的中药组合提取物及应用 | |
KR20150100288A (ko) | 흑효모로 발효한 생약추출물을 함유하는 화장료 조성물 | |
CN106377489A (zh) | 一种多功效化妆品及制作方法 | |
CN106236676B (zh) | 一种具有抗衰老功效的植物组合物及其应用 | |
CN113018238A (zh) | 一种抑菌消炎清爽益肤的祛痘凝胶及其制备方法 | |
CN109528615B (zh) | 一种凝胶型白及美白面膜及其制备方法 | |
KR20130015339A (ko) | 여드름 치료용 크림 조성물 | |
CN113491651A (zh) | 一种含山茶提取物的舒缓修护面膜精华液及其制备方法和应用 | |
KR101474340B1 (ko) | 생약 발효 추출물을 포함하는 피부 노화 방지 화장료조성물 | |
KR101494407B1 (ko) | 피부 온도 감응형 하이드로 겔을 이용한 기미개선 패치 및 그 제조방법 | |
KR101142541B1 (ko) | 효소처리를 이용한 혼합생약재 추출물을 함유하는 피부 주름개선용 화장료 조성물 및 그 추출방법 | |
CN114469826B (zh) | 一种凝胶型浙麦冬美白面膜及其制备方法 | |
CN105342933B (zh) | 一种中药复方洁面泡腾片及其制备方法 | |
CN113509426A (zh) | 一种具有修复妊娠纹和肥胖纹的植物提取复合物及其制备方法和应用 | |
CN109966193A (zh) | 一种改善皮肤功能的组合物及其制备方法和应用 | |
CN108703911B (zh) | 一种具有保湿美白功效的组合物及其制备方法和应用 | |
TW201201865A (en) | Glutathione production promoter, and pharmaceuticals, food, and cosmetic material having glutathione production promoting function | |
CN105663595B (zh) | 一种黑色素抑制剂、护肤组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |